Takeda Racks Up Designations for Rare Lung Cancer Drug

The U.S. Food and Drug Administration (FDA) today awarded a number of approvals for Takeda Pharmaceutical’s candidate drug EXKIVITY in the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer. 

Takeda was granted priority review and received a Breakthrough Therapy designation, Fast Track designation, and Orphan Drug designation, as the first and only approved oral therapy designed to target epidermal growth factor receptor (EGFR) Exon20 insertion mutations. EXKIVITY, also called mobocertinib, is a first-in-class oral tyrosine kinase inhibitor (TKI) indicated for NSCLC cases that have progressed on or after platinum-based chemotherapy. 

Patients with EGFR Exon20+ NSCLC make up around one to two percent of patients, and the disease is more common in Asian populations than in Western communities. It carries a worse prognosis compared to other EGFR mutations and current chemotherapy interventions provide little to no benefit. 

To Read the Complete Article at BioSpace Click Here

Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use, reference to, or reliance on any information contained within the article. Content available through the site may contain links and information to other websites. Links from BioPharma Global to third-party sites do not constitute an endorsement by BioPharma Global of the mentioned parties.

BioPharma Global is a mission-driven corporation, operating like a not-for-profit, dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with a high unmet medical need. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.

Stock image by SergeyNivens from Depositphotos

Comments are closed.